SavedAdd your journal

Journals / Van Tıp Dergisi / 2022 / Cilt: 29 - Sayı: 1

Amiodarone-Induced Pulmonary Toxicity in a Patient With Paroxysmal Atrial Fibrillation and Recurrence of Pulmonary Toxicity

Paroksismal Atriyal Fibrilasyonlu Hastada Amiodarona Bağlı Akciğer Toksisitesi ve Rekürrensi

Nuri Köse
Tarık Yıldırım
Pages
136–140
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this manuscript, we presented a 62 years- old woman who developed pu lmonary toxicity due to amiodarone therapy, recovered with corticosteroid therapy but relapsed after stopping this therapy, and finally recovered completely after long term use of steroid therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amiodarone is an effective anti-arrhythmic agent widely used for management of supraventricular and ventricular arrhythmias.
📊
Key Findings & Data:Amiodarone-induced pulmonary toxicity is one of the most serious side effects of amiodarone therapy.
💡
Conclusion & Impact:In this manuscript, we presented a 62 years- old woman who developed pu lmonary toxicity due to amiodarone therapy, recovered with corticosteroid therapy but relapsed after stopping this therapy, and finally recovered completely after long term use of steroid therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Amiodarone is an effective anti-arrhythmic agent widely used for management of supraventricular and ventricular arrhythmias. Amiodarone-induced pulmonary toxicity is one of the most serious side effects of amiodarone therapy. Patients who have developed pulmonary to xicity usually present with nonspecific symptoms such as cough, dyspnea, fever, and weight loss. Radiologically, amiodarone toxicity can manifest as a focal lesion or diffuse interstitial abnormality. Treatment involves immediate discontinuation of amiodarone and administration of corticosteroids for prompt recovery. Because of its long elimination half-life, pulmonary toxicity may initially progress despite drug discontinuation and may recur upon steroid withdrawal. In this manuscript, we presented a 62 years- old woman who developed pu lmonary toxicity due to amiodarone therapy, recovered with corticosteroid therapy but relapsed after stopping this therapy, and finally recovered completely after long term use of steroid therapy.

Özet

Amiodaron supraventriküler ve ventriküler aritmilerin tedavisinde yaygın olarak kullanılan etkili bira ntiaritmikajandır. Amiodaron ilişkili pulmoner toksisite, amiodaron tedavisinin çok ciddi biryani etkisidir. Pulmonertoksisite gelişen hastalarda genellikle öksürük, nefesdarlığı, ateşve kilo kayb ı gibi nonspesifik semptomlar mevcu ttur. Amiodarontoksisite siradyolojik olarak diffüzintertisyelan ormallikler ve yafokallezyonlar olarak görülebilir. Tedavi, amiodaronun derhal kesilmesi ve hızlı iyileşme için kortikosteroid verilmesini içerir. Amiodaronunuzun yar ılanma ömrü nedeniyle pulmonertoksisite ilacın kesilmesine ragmen ilerleyebilir vesteroidin kesilmesi ile tekrarlayabilir. Bu yaz ıda, amiarontedavisine ba ğlı pulmonertoksisite gelişen ve kortikosteroid tedavisi ile iyileşen, tedavinin erken kesilmesi ile nüks gelişen ve steroid tedavisinin uzun sure kullanılması ile tam iyileşen 62 ya şında bir kad ın hastayı sunduk.

🔖

Cite This Article

Köse, N., Yıldırım, T. (2022). Amiodarone-Induced Pulmonary Toxicity in a Patient With Paroxysmal Atrial Fibrillation and Recurrence of Pulmonary Toxicity. Van Tıp Dergisi, Cilt: 29 - Sayı: 1, 136–140. https://ajindex.com/articles/645892

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Van Cott TE, Yehle KS, DeCrane SK, Thorlton JR. Amiodarone-induced pulmonary toxicity: case study with syndrome analysis. Heart Lung 2013;42(4):262-266
  2. Fadahunsi O, Krol R. Acute amiodarone pulmonary toxicity following lung resection. Int J Biomed Sci 2014;10(3):217-220
  3. Garg J, Agrawal N, Marballi A, Agrawal S, Rawat N, Sule S, et al. Amiodarone induced pulmonary toxicity: An unusual response to steroids. Am J Case Rep 2012;13:62-65
  4. Nacca N, Bhamidipati CM, Yuhico LS, Pinnamaneni S, Szombathy T. Severe amiodarone induced pu lmonary toxicity. J Thorac Dis 2012;4(6):667-670
  5. Lee W, Ryu DR, Han SS, Ryu SW, Cho BR, Kwon H, et al. Very early onset of amiodarone-induced pulmonary toxicity. Korean Circ J 2013;43(10):699-701
  6. Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W. Amiodarone- induced pulmonary toxicity: an under- recognized and severe adverse effect? Clin Res Cardiol 2010;99(11):693-700
  7. Ott MC, Khoor A, Leventhal JP, Paterick TE, Burger CD. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003;123(2):646-651
  8. Okayasu K, Takeda Y, Kojima J, Yoshizawa A, Kobayashi N, Sugiyama H, et al. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity an d consideration of the probable risk for relapse. Intern Med 2006;45(22):1303-1307
  9. Endoh Y, Hanai R, Uto K, Uno M, Nagashima H, Narimatsu A, et al. KL-6 as a potential new marker for amiodarone- induced pulmonary toxicity. Am J Cardiol 2000;86(2):229-231
  10. Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007;71(10):1610-1616
  11. Fabiani I, Tacconi D, Grotti S, Brandini R, Salvadori C, Caremani M, et al. Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edema. J Cardiovasc Med (Hagerstown) 2011;12(5):361-365
  12. Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity Drug Saf 2010;33(7):539-558.